NASDAQ:IRIX - Nasdaq - US4626841013 - Common Stock - Currency: USD
NASDAQ:IRIX (5/28/2025, 8:00:02 PM)
0.948
+0.01 (+0.53%)
The current stock price of IRIX is 0.948 USD. In the past month the price decreased by -19.66%. In the past year, price decreased by -60.99%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.62 | 229.69B | ||
ISRG | INTUITIVE SURGICAL INC | 72.3 | 197.99B | ||
BSX | BOSTON SCIENTIFIC CORP | 38.71 | 154.62B | ||
SYK | STRYKER CORP | 30.36 | 145.37B | ||
MDT | MEDTRONIC PLC | 14.77 | 104.19B | ||
BDX | BECTON DICKINSON AND CO | 12.28 | 49.59B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.48 | 44.97B | ||
IDXX | IDEXX LABORATORIES INC | 45.12 | 41.68B | ||
RMD | RESMED INC | 26.96 | 35.89B | ||
DXCM | DEXCOM INC | 52.72 | 34.11B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.47 | 32.58B | ||
STE | STERIS PLC | 26.23 | 24.07B |
IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company is headquartered in Mountain View, California and currently employs 93 full-time employees. The company develops and commercializes products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probes products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.
IRIDEX CORP
1212 Terra Bella Ave
Mountain View CALIFORNIA 94043 US
CEO: David I. Bruce
Employees: 93
Phone: 16509404700
The current stock price of IRIX is 0.948 USD. The price increased by 0.53% in the last trading session.
The exchange symbol of IRIDEX CORP is IRIX and it is listed on the Nasdaq exchange.
IRIX stock is listed on the Nasdaq exchange.
IRIDEX CORP (IRIX) has a market capitalization of 15.92M USD. This makes IRIX a Nano Cap stock.
IRIDEX CORP (IRIX) currently has 93 employees.
IRIDEX CORP (IRIX) has a support level at 0.94 and a resistance level at 1.02. Check the full technical report for a detailed analysis of IRIX support and resistance levels.
The Revenue of IRIDEX CORP (IRIX) is expected to grow by 5.44% in the next year. Check the estimates tab for more information on the IRIX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IRIX does not pay a dividend.
IRIDEX CORP (IRIX) will report earnings on 2025-08-06, after the market close.
IRIDEX CORP (IRIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.43).
The outstanding short interest for IRIDEX CORP (IRIX) is 2.14% of its float. Check the ownership tab for more information on the IRIX short interest.
ChartMill assigns a fundamental rating of 1 / 10 to IRIX. IRIX has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months IRIX reported a non-GAAP Earnings per Share(EPS) of -0.43. The EPS increased by 35.82% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -20.83% | ||
ROE | -104.09% | ||
Debt/Equity | 0.53 |
ChartMill assigns a Buy % Consensus number of 43% to IRIX. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 49% and a revenue growth 5.44% for IRIX